MD726Z - Method for prognosticating the evolution of gastric precancerous states in men - Google Patents
Method for prognosticating the evolution of gastric precancerous states in men Download PDFInfo
- Publication number
- MD726Z MD726Z MDS20130132A MDS20130132A MD726Z MD 726 Z MD726 Z MD 726Z MD S20130132 A MDS20130132 A MD S20130132A MD S20130132 A MDS20130132 A MD S20130132A MD 726 Z MD726 Z MD 726Z
- Authority
- MD
- Moldova
- Prior art keywords
- gastric
- evolution
- secretion
- interleukin
- determined
- Prior art date
Links
- 230000002496 gastric effect Effects 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 25
- 208000006994 Precancerous Conditions Diseases 0.000 title claims abstract description 21
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 22
- 230000028327 secretion Effects 0.000 claims abstract description 18
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 12
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 12
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 12
- 210000002784 stomach Anatomy 0.000 claims abstract description 11
- 229960003604 testosterone Drugs 0.000 claims abstract description 11
- 210000001519 tissue Anatomy 0.000 claims abstract description 7
- 210000003296 saliva Anatomy 0.000 claims abstract description 5
- 108010079943 Pentagastrin Proteins 0.000 claims abstract description 4
- 229960000444 pentagastrin Drugs 0.000 claims abstract description 4
- 230000027119 gastric acid secretion Effects 0.000 claims abstract description 3
- 210000001156 gastric mucosa Anatomy 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 238000003127 radioimmunoassay Methods 0.000 abstract description 3
- 238000004393 prognosis Methods 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000020123 juvenile polyp Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la gastrooncologie şi poate fi utilizată pentru pronosticarea evoluţiei stărilor precanceroase gastrice la bărbaţi. The invention relates to medicine, in particular to gastro-oncology and can be used to predict the evolution of gastric precancerous conditions in men.
Se cunoaşte că depistarea şi tratamentul stărilor precanceroase ale stomacului reprezintă profilaxia secundară a cancerului gastric (Беспалов В. Г. Индивидуальная профилактика рака. Питер, 2001, p. 123-126). It is known that the detection and treatment of precancerous conditions of the stomach represents the secondary prophylaxis of gastric cancer (Bespalov V. G. Individual cancer prevention. Peter, 2001, p. 123-126).
În prezent la principalele stări precanceroase ale stomacului se referă gastrita cronică atrofică, ulcerul gastric şi duodenal cronic şi infectarea cu Helicobacter pylori, iar la schimbările precanceroase principale se referă metaplazia intestinală şi displazia intestinală a epiteliului gastric (Аруин Л. И., Капуллер Л. Л., Исаков В. А. Морфологическая диагностика желудка и кишечника. Москва, Триада-Х, 1998, p. 269-300). Currently, the main precancerous conditions of the stomach include chronic atrophic gastritis, chronic gastric and duodenal ulcers, and Helicobacter pylori infection, and the main precancerous changes include intestinal metaplasia and intestinal dysplasia of the gastric epithelium (Aruin L. I., Kapuller L. L., Isakov V. A. Morphological diagnosis of the stomach and intestines. Moscow, Triada-X, 1998, p. 269-300).
Unul dintre factorii principali ai apariţiei cancerului gastric îl constituie compuşii ce conţin nitraţi şi amine în sucul gastric (Bartsch H., Frank N., Blocking the endogenous formation N-nitroso compounds and related carcenogens// In. Principles of Chemoprevention Ed. By. B. W. Stevart, D. Mc. Gregor, P. Kleihues - IARC Sci. Publ. Nr. 139, Lyon, France: International Agency for Research on Cancer, 1996, p. 189-201). One of the main factors in the occurrence of gastric cancer is the compounds containing nitrates and amines in the gastric juice (Bartsch H., Frank N., Blocking the endogenous formation N-nitroso compounds and related carcinogens// In. Principles of Chemoprevention Ed. By. B. W. Stevart, D. Mc. Gregor, P. Kleihues - IARC Sci. Publ. No. 139, Lyon, France: International Agency for Research on Cancer, 1996, p. 189-201).
Este cunoscută metoda de pronostic al evoluţiei patologiei oncologice care constă în aceea că se colectează sânge, se pun în evidenţă leucocitele şi neutrofilele, apoi în leucocite se determină nivelul de histamină timp de 4…5 zile şi se calculează raportul valorilor de histamină din limfocite faţă de cantitatea de amină din neutrofile, în cazul în care se obţin valori mai mari de 0,9 se pronostichează o evoluţie nefavorabilă a patologiilor oncologice gastrice [1]. There is a known method for predicting the evolution of oncological pathology, which consists of collecting blood, highlighting leukocytes and neutrophils, then determining the histamine level in leukocytes for 4...5 days and calculating the ratio of histamine values in lymphocytes to the amount of amine in neutrophils. If values higher than 0.9 are obtained, an unfavorable evolution of gastric oncological pathologies is predicted [1].
Dezavantajul acestei metode constă în aceea că nivelul sporit de histamină poate fi prezent într-un şir de patologii de origine alergică şi la utilizarea unui şir de remedii medicamentoase, ceea ce face această metodă de pronosticare inexactă şi poate duce la aplicarea unei tactici de tratament greşite. The disadvantage of this method is that increased histamine levels can be present in a number of allergic pathologies and with the use of a number of medications, which makes this method of prediction inaccurate and may lead to the application of the wrong treatment tactics.
În calitate de cea mai apropiată soluţie se cunoaşte metoda de pronostic al evoluţiei bolii ulceroase duodenale, ce constă în aceea că se precizează vârsta bolnavului, ereditatea, grupa sangvină, deficitul de masă corporală, caracterul sindromului dureros, se efectuează testul cu atropină şi se determină endoscopic localizarea, dimensiunea, timpul de cicatrizare a defectului ulceros, precum şi forma gastritei şi/sau bulbitei, datelor obţinute li se atribuie următoarele valori: dacă vârsta bolnavului coincide sau este mai mare de 35 ani - 0,5, mai mică de 35 ani - 2; antecedente eredocolaterale patologice - 2; I grupă sangvină - 1; deficit de masă corporală - 1,5; sindrom dureros pronunţat - 2, moderat - 0,5; test cu atropină pozitiv - 0,5, negativ - 3; localizarea defectului ulceros pe peretele anterior şi/sau medial al bulbului duodenal - 1, pe peretele lui posterior - 2; dimensiunea defectului ulceros în diametru până la 0,9 cm - 0,5, de la 1,0 cm până la 1,5 cm - 1, mai mare de 1,5 cm - 3; timpul de cicatrizare a lui până la 39 zile - 0,5, de la 40 până la 58 zile - 1, mai mult de 58 zile - 4; gastrită antrală superficială şi/sau bulbită - 0,5, erozivă - 4; după aceasta valorile obţinute se sumează, în cazul în care suma valorilor este egală sau mai mică decât 10, se face pronosticul unei evoluţii favorabile a bolii ulceroase duodenale, iar când suma valorilor este egală sau mai mare decât 12, se face pronosticul unei evoluţii nefavorabile a bolii ulceroase [2]. As the closest solution, the method of prognosis of the evolution of duodenal ulcer disease is known, which consists in specifying the patient's age, heredity, blood group, body mass deficiency, the nature of the pain syndrome, performing the atropine test and determining endoscopically the location, size, healing time of the ulcer defect, as well as the form of gastritis and/or bulbitis, the following values are assigned to the obtained data: if the patient's age coincides with or is older than 35 years - 0.5, less than 35 years - 2; pathological hereditary collateral history - 2; I blood group - 1; body mass deficiency - 1.5; pronounced pain syndrome - 2, moderate - 0.5; positive atropine test - 0.5, negative - 3; localization of the ulcer defect on the anterior and/or medial wall of the duodenal bulb - 1, on its posterior wall - 2; the size of the ulcer defect in diameter up to 0.9 cm - 0.5, from 1.0 cm to 1.5 cm - 1, more than 1.5 cm - 3; its healing time up to 39 days - 0.5, from 40 to 58 days - 1, more than 58 days - 4; superficial antral gastritis and/or bulbitis - 0.5, erosive - 4; after this, the obtained values are summed up, if the sum of the values is equal to or less than 10, a favorable evolution of duodenal ulcer disease is predicted, and when the sum of the values is equal to or greater than 12, an unfavorable evolution of ulcer disease is predicted [2].
Dezavantajul acestei metode este dificultatea în aplicare, precum şi faptul că e posibil de pronosticat numai particularităţile evolutive ale ulcerului gastroduodenal nu şi procesul de malignizare al acestei stări precanceroase. The disadvantage of this method is the difficulty in application, as well as the fact that it is possible to predict only the evolutionary particularities of the gastroduodenal ulcer, not the malignancy process of this precancerous condition.
Problema pe care o soluţionează invenţia propusă constă în elaborarea unei metode exacte, simple şi uşor aplicabile în practica de pronosticare a evoluţiei stărilor precanceroase ale stomacului la bărbaţi, pentru a adopta o tactică de tratament eficientă şi a evita malignizarea stărilor precanceroase. The problem solved by the proposed invention consists in developing an accurate, simple and easily applicable method in practice for predicting the evolution of precancerous conditions of the stomach in men, in order to adopt an effective treatment tactic and avoid the malignancy of precancerous conditions.
Conform invenţiei, metoda revendicată constă în aceea că se colectează 2…4 ml de salivă şi se determină cantitatea interleucinei 6. Apoi în stomac se introduce o sondă gastrică şi se aspiră secreţia gastrică bazală în 4 probe, recoltate continuu, la intervale de 15 min, după care, subcutanat, se administrează un stimulator al secreţiei gastrice - pentagastrin 6 mg/kg, şi se aspiră repetat secreţia gastrică bazală în 4 probe, recoltate continuu, la intervale de 15 min. Se determină secreţia gastrică totală. Se efectuează fibrogastroscopia şi se prelevă o porţiune din mucoasa gastrică din zona adiacentă a afecţiunii, în care prin metoda radioimună se determină nivelul de testosteron. În cazul în care valorile secreţiei acidului clorhidric sunt mai mici de 4 mmol/oră, cantitatea interleucinei 6 este mai mare de 47 ng/ml, iar nivelul testosteronului în ţesut este mai mic de 21 ng/ml se pronostichează o evoluţie nefavorabilă a stărilor precanceroase. According to the invention, the claimed method consists in collecting 2…4 ml of saliva and determining the amount of interleukin 6. Then a gastric probe is inserted into the stomach and the basal gastric secretion is aspirated in 4 samples, collected continuously, at intervals of 15 min, after which, subcutaneously, a stimulator of gastric secretion - pentagastrin 6 mg/kg is administered, and the basal gastric secretion is repeatedly aspirated in 4 samples, collected continuously, at intervals of 15 min. The total gastric secretion is determined. Fibrogastroscopy is performed and a portion of the gastric mucosa is taken from the adjacent area of the disease, in which the testosterone level is determined by the radioimmunoassay method. If the hydrochloric acid secretion values are lower than 4 mmol/hour, the amount of interleukin 6 is higher than 47 ng/ml, and the testosterone level in the tissue is lower than 21 ng/ml, an unfavorable evolution of precancerous conditions is predicted.
Rezultatul invenţiei constă în elaborarea unei metode simple şi exacte de pronostic al patologiilor precanceroase gastrice la bărbaţi, care permite stabilirea tacticii de tratament pe viitor în scopul evitării malignizării stărilor precanceroase. Rezultatul se datorează faptului că concomitent se determină valorile sucului gastric, ale interleucinei 6 şi ale testosteronului. The result of the invention consists in developing a simple and accurate method for the prognosis of gastric precancerous pathologies in men, which allows establishing future treatment tactics in order to avoid malignancy of precancerous conditions. The result is due to the fact that the values of gastric juice, interleukin 6 and testosterone are simultaneously determined.
Avantajele metodei revendicate constau în aceea că este simplă în aplicare, nu este costisitoare şi este exactă în determinarea pronosticului. Veridicitatea pronosticului efectuat cu ajutorul metodei revendicate a fost confirmat prin controlul pacienţilor la un an după pronosticare. Din toţi cei 86 de pacienţi la care s-a stabilit un pronostic favorabil, la toţi peste un an clinic şi paraclinic evoluţia stării precanceroase a fost confirmată ca favorabilă. Iar 14 pacienţi, la care s-a stabilit un pronostic nefavorabil, au fost operaţi şi au primit tratament conservativ specific postoperator, apoi la un an după operaţie recidive nu s-au atestat. 20 de pacienţi au refuzat tratamentul chirurgical şi specific conservativ şi la un an de zile la toţi 20 s-a confirmat histologic pronosticul nefavorabil, adică starea precanceroasă s-a malignizat. În total au fost examinaţi 120 de pacienţi. The advantages of the claimed method are that it is simple to implement, inexpensive and accurate in determining the prognosis. The veracity of the prognosis made using the claimed method was confirmed by monitoring the patients one year after the prognosis. Of all 86 patients in whom a favorable prognosis was established, in all of them over one year the clinical and paraclinical evolution of the precancerous condition was confirmed as favorable. And 14 patients in whom an unfavorable prognosis was established were operated on and received specific conservative postoperative treatment, then one year after the operation no relapses were recorded. 20 patients refused surgical and specific conservative treatment and after one year in all 20 the unfavorable prognosis was confirmed histologically, i.e. the precancerous condition had become malignant. In total, 120 patients were examined.
Metoda de pronosticare a evoluţiei stărilor precanceroase la bărbaţi se efectuează în felul următor: la pacienţii cu stări precanceroase gastrice în salivă se determină cantitatea de interleucină 6 în felul următor: dimineaţa pe stomacul gol, după o prelucrare a cavităţii bucale cu o soluţie de permagnat de caliu, se colectează 2…4 ml de salivă şi se păstrează până la analiză la temperatura de -20°C. Determinarea interleucinei 6 se efectuează utilizând metoda imunofermentativă de analiză la dispozitivul de analizare STAT Fax (USA). Apoi în stomac se introduce o sondă gastrică şi se aspiră secreţia gastrică bazală în 4 probe, recoltate continuu, la intervale de 15 min, după care subcutanat se administrează un stimulator al secreţiei gastrice - pentagastrin 6 mg/kg, şi se aspiră repetat secreţia gastrică bazală în 4 probe, recoltate continuu, la intervale de 15 min. În fiecare doză de suc gastric se determină cantitatea (ml) şi concentraţia sucului gastric conform metodei elaborate de Şihaălis, după care se calculează secreţia gastrică totală după metoda clasică descrisă (Козловская Л. В., Николаев А. Ю. Учебное пособие по клиническим и лабораторным методам исследования. Москва, Медицина, 1984, p. 207-221; Фишзон-Рысс Ю. И. Современные методы исследования. Ленинград. Медицина, 1972, p. 106-127), totodată se efectuează fibrogastroscopia şi se colectează ţesut gastric din zona adiacentă (0,5…1,0 cm) de la marginea stării precanceroase gastrice. Prin metoda radioimună se determină cantitatea de testosteron. În cazul în care se determină valori în care cantitatea totală a sucului gastric este mai mică de 4 mmol/oră, cantitata interleucinei 6 este mai mare de 47 ng/ml, iar nivelul testosteronului în ţesutul adiacent stării precanceroase este mai mic de 21 ng/ml, se pronostichează o evoluţie nefavorabilă a patologiei precanceroase. The method of predicting the evolution of precancerous conditions in men is performed as follows: in patients with gastric precancerous conditions in saliva, the amount of interleukin 6 is determined as follows: in the morning on an empty stomach, after processing the oral cavity with a potassium permanganate solution, 2…4 ml of saliva is collected and stored until analysis at a temperature of -20°C. Interleukin 6 is determined using the immunofermentative analysis method on the STAT Fax analysis device (USA). Then a gastric probe is inserted into the stomach and the basal gastric secretion is aspirated in 4 samples, collected continuously, at intervals of 15 min, after which a gastric secretion stimulator is administered subcutaneously - pentagastrin 6 mg/kg, and the basal gastric secretion is repeatedly aspirated in 4 samples, collected continuously, at intervals of 15 min. In each dose of gastric juice, the quantity (ml) and concentration of gastric juice are determined according to the method developed by Şihaălis, after which the total gastric secretion is calculated according to the classical method described (Kozlovskaya L. V., Nikolaev A. Yu. Textbook on clinical and laboratory research methods. Moscow, Medicine, 1984, p. 207-221; Fishzon-Ryss Yu. I. Modern research methods. Leningrad. Medicine, 1972, p. 106-127), at the same time, fibrogastroscopy is performed and gastric tissue is collected from the adjacent area (0.5…1.0 cm) from the edge of the gastric precancerous condition. The amount of testosterone is determined by the radioimmunoassay method. If values are determined in which the total amount of gastric juice is less than 4 mmol/hour, the amount of interleukin 6 is greater than 47 ng/ml, and the testosterone level in the tissue adjacent to the precancerous condition is less than 21 ng/ml, an unfavorable evolution of the precancerous pathology is predicted.
Exemple concrete de realizare Concrete examples of implementation
Exemplul 1 Example 1
Pacientului A., în vârstă de 55 ani, cu diagnosticul clinic de gastrită cronică atrofică, polip juvenil pe curbura mică a stomacului, i s-a aplicat metoda de pronosticare revendicată, obţinându-se următoarele valori: secreţia totală a sucului gastric - 4 mmol/oră, cantitatea interleucinei 6 - 32 ng/ml, nivelul testosteronului în ţesutul adiacent stării precanceroase - 41 ng/ml. S-a pronosticat o evoluţie favorabilă, care a fost confirmată histologic peste 1 an. Patient A., 55 years old, with a clinical diagnosis of chronic atrophic gastritis, juvenile polyp on the lesser curvature of the stomach, was applied the claimed prognostic method, obtaining the following values: total secretion of gastric juice - 4 mmol/hour, the amount of interleukin 6 - 32 ng/ml, the level of testosterone in the tissue adjacent to the precancerous condition - 41 ng/ml. A favorable evolution was predicted, which was histologically confirmed after 1 year.
Exemplul 2 Example 2
Pacientului B., în vârstă de 46 ani, cu diagnosticul clinic de ulcer gastric cronic pe curbura mică a stomacului, infectare cu Helicobacter pylori, polip adenomatos în regiunea pilorului gastric, i s-a aplicat metoda de pronosticare revendicată, obţinându-se următoarele valori: secreţia totală a sucului gastric - 2,7 mmol/oră, cantitatea interleucinei 6 - 68 ng/ml, nivelul testosteronului în ţesutul adiacent stării precanceroase - 14 ng/ml. S-a pronosticat o evoluţie nefavorabilă, care a fost confirmată histologic, peste un an depistându-se o adenocarcenomă pilorică a stomacului. Patient B., 46 years old, with a clinical diagnosis of chronic gastric ulcer on the lesser curvature of the stomach, Helicobacter pylori infection, adenomatous polyp in the region of the gastric pylorus, was applied the claimed prognostic method, obtaining the following values: total secretion of gastric juice - 2.7 mmol/hour, the amount of interleukin 6 - 68 ng/ml, the level of testosterone in the tissue adjacent to the precancerous condition - 14 ng/ml. An unfavorable evolution was predicted, which was confirmed histologically, after a year a pyloric adenocarcinoma of the stomach was detected.
1. RU 2018835 C1 1984.08.30 1. RU 2018835 C1 1984.08.30
2. MD 1732 G2 2002.03.31 2. MD 1732 G2 2002.03.31
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130132A MD726Z (en) | 2013-07-23 | 2013-07-23 | Method for prognosticating the evolution of gastric precancerous states in men |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130132A MD726Z (en) | 2013-07-23 | 2013-07-23 | Method for prognosticating the evolution of gastric precancerous states in men |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD726Y MD726Y (en) | 2014-01-31 |
| MD726Z true MD726Z (en) | 2014-08-31 |
Family
ID=50071914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20130132A MD726Z (en) | 2013-07-23 | 2013-07-23 | Method for prognosticating the evolution of gastric precancerous states in men |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD726Z (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018835C1 (en) * | 1990-11-11 | 1994-08-30 | Гаркави Любовь Хаимовна | Method of prognosis of oncologic disease course |
| MD1043G2 (en) * | 1998-06-09 | 1999-04-30 | Виктория ЧЕРЕШ | Method for ulcer desease recidivation prognosis |
| MD1732G2 (en) * | 2001-05-02 | 2002-03-31 | Ion Tabarna | Method of prognosticating the duodenal ulcerous disease evolution |
| MD239Z (en) * | 2010-02-15 | 2011-02-28 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Method of predicting the clinical development of I stage breast cancer |
| MD369Z (en) * | 2011-01-03 | 2011-12-31 | Лилиан ШАРТЕФРАЦЬ | Method for predicting the risk of recurrence or malignization of precancerous process of the neck of uterus |
| MD654Y (en) * | 2012-11-20 | 2013-07-31 | Valeriu Palade | Method for predicting the course of II and III stage malignant melanoma |
-
2013
- 2013-07-23 MD MDS20130132A patent/MD726Z/en not_active IP Right Cessation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018835C1 (en) * | 1990-11-11 | 1994-08-30 | Гаркави Любовь Хаимовна | Method of prognosis of oncologic disease course |
| MD1043G2 (en) * | 1998-06-09 | 1999-04-30 | Виктория ЧЕРЕШ | Method for ulcer desease recidivation prognosis |
| MD1732G2 (en) * | 2001-05-02 | 2002-03-31 | Ion Tabarna | Method of prognosticating the duodenal ulcerous disease evolution |
| MD239Z (en) * | 2010-02-15 | 2011-02-28 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Method of predicting the clinical development of I stage breast cancer |
| MD369Z (en) * | 2011-01-03 | 2011-12-31 | Лилиан ШАРТЕФРАЦЬ | Method for predicting the risk of recurrence or malignization of precancerous process of the neck of uterus |
| MD654Y (en) * | 2012-11-20 | 2013-07-31 | Valeriu Palade | Method for predicting the course of II and III stage malignant melanoma |
Also Published As
| Publication number | Publication date |
|---|---|
| MD726Y (en) | 2014-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moss et al. | Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. | |
| Agha-Hosseini et al. | Serum and saliva collagenase-3 (MMP-13) in patients with oral lichen planus and oral squamous cell carcinoma | |
| Lahner et al. | Atrophic gastritis and pre-malignant gastric lesions | |
| Iwakiri et al. | Esophageal motility in Japanese patients with Barrett’s esophagus | |
| Muszyński et al. | Gastritis–facts and doubts | |
| MD726Z (en) | Method for prognosticating the evolution of gastric precancerous states in men | |
| Johnston et al. | Effect of acid in the duodenum on histamine-stimulated gastric secretion in man | |
| US20210116453A1 (en) | Methods and materials for assessing and treating lichen planus | |
| Fulton et al. | Nail bed immunofluorescence in pemphigus vulgaris | |
| RU2411907C1 (en) | Method of predicting lung cancer metastases | |
| RU2533248C1 (en) | Qualitative differential instant diagnostic technique for periglottis growths shown by patient's oral fluid biomarkers | |
| Hughes et al. | The effect of the alkaline tide on serum-ionized calcium concentration in man | |
| Silva et al. | Gastrinaemia, tissue gastrin concentration and G cell density in the antral mucosa of swine with and without gastric ulcer of the pars oesophagea | |
| RU2535076C1 (en) | Method of qualitative differential express-diagnostics of lip mucosa neoplasms by content of biomarkers in patient's oral fluid | |
| RU2648765C1 (en) | Method for qualitative determination of dental status of patient with inflammation of alveolar mucosa based on content of biomarkers in oral fluid | |
| CN112240932A (en) | Application of KNG1 protein expressed by urine of lung cancer patient | |
| CN117907596B (en) | Breast cancer early diagnosis marker, kit and application thereof | |
| SU1343358A1 (en) | Method of diagnostics of celiac disease | |
| Berker et al. | Prevalence and recurrence rate of colonic lesions in acromegalic patients | |
| RU2657786C1 (en) | Method for diagnosing activity of duodenal ulcer | |
| Hirasaki et al. | Multiple synchronous early gastric carcinoma with seven lesions | |
| Fontana et al. | Changes in Humoral Biomarkers (Klotho) in Patients with Haematological Tumors Undergoing Chemotherapy and Allogeneic Bone Marrow Transplantation Developing AKI: PO1904 | |
| RU2527676C1 (en) | Qualitative differential instant diagnostic technique for parotid gland growths shown by patient's oral fluid biomarkers | |
| Gamboa et al. | The descriptive epidemiology of gastrointestinal malignancies | |
| Velappan et al. | CLINICOPATHOLOGICAL PROFILE OF COLORECTAL CANCER PATIENTS YOUNGER THAN 50 YEARS: A STUDY FROM SOUTH INDIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |